Table 4.

Comparison of OAC non-persistence among OAC naïve patients

		95% CI
	HR	Lower	Upper	p Value
During the first 2 months of follow-up (N=11 647)
Index medication (reference category: apixaban)
Rivaroxaban	1.49	1.00	2.22	0.052
Dabigatran	1.65	1.08	2.52	0.022
VKA	0.33	0.22	0.48	<0.001
History of stroke risk factors (yes vs no)
Vascular disease	0.81	0.66	0.99	0.037
Hypertension	0.81	0.68	0.96	0.015
Concomitant therapy* (yes vs no)
Aspirin	2.79	2.30	3.38	<0.001
Other antiplatelet	1.89	1.40	2.54	<0.001
After the first 2 months of follow-up (N=10 977)
Index medication (reference category: apixaban)
Rivaroxaban	1.58	0.98	2.55	0.059
Dabigatran	2.10	1.30	3.41	0.003
VKA	1.70	1.08	2.66	0.021
Demographics
Age at index date (years)	0.99	0.98	0.99	<0.001
Country (reference category: England)
Wales	0.57	0.48	0.68	<0.001
Scotland	1.14	0.99	1.31	0.078
Northern Ireland	0.84	0.66	1.07	0.151
History of stroke risk factors (yes vs no)
Vascular disease	0.89	0.80	0.99	0.036
Hypertension	0.88	0.80	0.96	0.005
Concomitant therapy* (yes vs no)
Parenteral anticoagulants	1.49	1.07	2.07	0.020
Aspirin	1.38	1.23	1.56	<0.001
Other antiplatelet	1.57	1.31	1.87	<0.001

*Concomitant therapy: prescribed on index date or within 3 months after index date.

OAC, oral anticoagulants; VKA, vitamin K antagonists.